Synthesis and evaluation of 4-acyl-2-thiazolylhydrazone derivatives for anti-Toxoplasma efficacy in vitro

Journal of Medicinal Chemistry

Volumn 52, Issue 15, 2009, Pages 4574-4577

  Chimenti, Franco ^a   Bizzarri, Bruna ^a   Bolasco, Adriana ^a   Secci, Daniela ^a   Chimenti, Paola ^a   Carradori, Simone ^a   Granese, Arianna ^a   Rivanera, Daniela ^a   Frishberg, Nathan ^b   Bordón, Claudia ^b   Jones Brando, Lorraine ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDRAZONE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; NONHUMAN; TACHYZOITE; TOXOPLASMA GONDII;

ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; HYDRAZONES; STRUCTURE-ACTIVITY RELATIONSHIP; TOXOPLASMA;

EID: 68549125302     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9005862     Document Type: Article

References (21)

1. Pfefferkorn, E. R. Cell Biology of Toxoplasma gondii. In Modern Parasite Biology; Wyler, D. J., Ed.; W.H. Freeman and Co.: New York, 1990; pp 26-50.
2. Mamidi, A.; De Simone, J. A.; Pomerantz, R. J. Central nervous system infections in individuals with HIV-1 infection. J. Neurovirol. 2002, 8, 158-167.
3. Lane, H. C.; Laughon, B. E.; Falloon, J.; Kovacs, J. A.; Davey, R. T.Jr.; Polis, M. A.; Masur, H. NIH conference. Recent advances in the management of AIDS-related opportunistic infections. Ann. Intern. Med. 1994, 120 (11), 945-955.
4. Klepser, M. E.; Lepser, T. B. Drug treatment of HIV-related opportunistic infections. Drugs 1997, 53, 40-73.
5. Montoya, J. G.; Liesenfeld, O. Toxoplasmosis. Lancet 2004, 363, 1965-1976.
6. Schurmann, D.; Bergmann, F.; Albrecht, H.; Padberg, J.; Wunsche, T.; Grunewald, T.; Schurmann, M.; Grobusch, M.; Vallee, M.; Ruf, B.; Suttorp, N. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21 (5), 353-361.
7. Petersen, E.; Schmidt, D. R. Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: What are the options?. Expert Rev. Anti-Infect. Ther. 2003, 1, 175-182.
8. Joss, A. W. L. In Human Toxoplasmosis; Ho-Yen, D. O., Joss, A. W. L., Eds.; Oxford University Press: New York, 1992; Vol. 120, p 5.
9. Subauste, C. S.; Remington, J. S. Immunity to Toxoplasma gondii. Curr. Opin. Immunol. 1993, 5, 532-537.
10. Weller, I. V. D.; Williams, I. G. ABC of AIDS. Treatment of infections. Br. Med. J. 2001, 322, 1350-1354.
11. Du, X.; Guo, C.; Hansell, E.; Doyle, P. S.; Caffrey, C. R.; Holler, T. P.; McKerrow, J. H.; Cohen, F. E. Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. 2002, 45, 2695-2707.
12. McKerrow, J. H.; Engel, J. C.; Caffrey, C. R. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. 1999, 7, 639-644.
13. Tenorio, R. P.; Carvalho, C. S.; Pessanha, C. S.; de Lima, J. G.; de Faria, A. R.; Alves, A. J.; de Melo, E. J. T.; Goes, A. J. S. Synthesis of thiosemicarbazone and 4-thiazolidinone derivatives and their in vitro anti-Toxoplasma gondii activity. Bioorg. Med. Chem. Lett. 2005, 15, 2575-2578.
14. de Aquino, T. M.; Liesen, A. P.; da Silva, R. E. A.; Lima, V. T.; Carvalho, C. S.; de Faria, A. R.; de Araujo, J. M.; de Lima, J. G.; Alves, A. J.; de Melo, E. J. T.; Goes, A. J. S. Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3- thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5- thiazolidineacetic acids. Bioorg. Med. Chem. 2008, 16, 446-456.
15. de Souza, M. V. N. Synthesis and biological activity of natural thiazoles: an important class of heterocyclic compounds. J. Sulfur Chem. 2005, 26, 429-449.
16. Usol'tseva, S. V.; Andronnikova, G. P.; Nikolaeva, S. L. Synthesis of 2-hydrazono-4-ethoxycarbonylthiazoles. Zh. Org. Khim. 1991, 27 (11), 2445-2450.
17. Foye, W. O.; Ghosh, K. Superoxide dismutase mimicking activity of copper(II) complexes of bis(methylthio) and methylthio amino derivatives of 1-methylpyridinium-(and quinolinium)-2-dithioacetic acids and other heterocyclic ligands. Trends Heterocycl. Chem. 1990, 1 (1), 9-17.
18. Jones-Brando, L.; Torrey, E. F.; Yolken, R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr. Res. 2003, 62, 237-244.
19. Huynh, M. H.; Rabenau, K. E.; Harper, J. M.; Beatty, W. L.; Sibley, L. D.; Carruthers, V. B. Rapid invasion of host cells by Toxoplasma requires secretion of the MIC2-M2AP adhesive protein complex. EMBO J. 2003, 22, 2082-2090.
20. Silverman, J. A.; Hayes, M. L.; Luft, B. J.; Joiner, K. A. Characterization of anti-Toxoplasma activity of SDZ 215-918 a cyclosporin derivative lacking immunosuppressive and peptidyl-prolylisomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology. Antimicrob. Agents Chemother. 1997, 41, 1859-1866.
21. Huynh, M. H.; Carruthers, V. Toxoplasma MIC2 is a major determinant of invasion and virulence. PLoS Pathog. 2006, 2, 753-762.